Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...

Migraine disease affects millions of Americans, but treatments often cause side effects that hinder sufferers' ability to function.

The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132 as the first prescription digital ...

Oral triptans are considered the industry gold standard acute treatments and there are currently seven approved, all with ...

Delivering room-temperature air through the nose to cool the sphenopalatine ganglion taps into a powerful neuromodulatory ...

For the first time in 30 years, a new drug class known as the CGRP-Antagonists (calcitonin gene-related peptide) has emerged.

recommendations are presented for the pharmacologic treatment of acute episodic migraine headache in the outpatient setting. Amir Qaseem, MD, PhD, from the ACP in Philadelphia, and colleagues ...

Compared with sham, transnasal dry air flow at 10 L per minute using the Mi-Helper device was effective in treating acute ...

The software-based intervention aims to reduce brain hypersensitivity in patients with migraine by modulating responses to environmental and internal stimuli through a 12-week program.

A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health ...

Fremanezumab is a calcitonin-gene related peptide (CGRP) pathway monoclonal antibody that is FDA approved for adults with ...